EUCTR2010-024551-82-GB进行中（未招募）1 期
OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS) - Atomoxetine in 22qDS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Children and adolescents of both genders, aged 7-17 years inclusive at the beginning of trial, with a genetically confirmed diagnosis of 22qDS.
- •2. Diagnosis of Attention Deficit Hyperactivity Disorder.
- •3. Access allowed to medical records
- •4. Participant is in a stable care situation.
- •5. Informed consent is obtained.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Children currently receiving atomoxetine will not be included. (Those who have received atomoxetine in the past regardless of response, may be included, provided they did not demonstrate frank intolerance, i.e. moderate to severe adverse effects at low doses).
- •2. A clear-cut history of intolerance to atomoxetine (defined as serious or moderate adverse events at very low doses eg 10mgs o.d)
- •3. Concomitant use of MAO inhibitor or narrow angle glaucoma (due to increased risk of mydriasis) represent absolute contradictions to the use of atomoxetine and constitute exclusion to the trial. MAOI use within the last 2 weeks or other drugs that affect brain monamine concentrations are also an exclusion
- •4. Severe limitation of mobility
- •5. Dementia or degenerative disorder
- •6. Poorly controlled or uncontrolled epilepsy
- •7. Presence of significant cardiovascular disease (Medical notes will be reviewed by a consulant paediatrician and further investigations undertaken, if necessary, to exclude any reason for inclusion).
- •8. Psychotic disorder or bipolar disorder.
- •9. Child has severe obsessive-compulsive disorder severe enough to require special treatment.
- •10. Child is being treated with neuroleptic or stimulant medication (children have to be off neuroleptic medication for at least 1 month and 1 week off stimulant medication prior to randomisation)
- •11. Child poses a significant risk of suicidal or homicidal behaviour
- •12. Children without a full-time school/college placement that is expected to continue for the next 4 months.
- •13. Another child the in family and/or household currently enrolled in this study
- •14. Children residing in a home without a telephone (land line or mobile)
- •15. Ongoing child protection concerns
- •16. For female participants, pregnancy or not wishing to have a pregnancy test at baseline, will be an exclusion criterion.
研究者
相似试验
Withheld
不适用
[Trial of device that is not approved or cleared by the U.S. FDA]NCT06762340[Redacted]
Withheld
不适用
[Trial of device that is not approved or cleared by the U.S. FDA]NCT04945941[Redacted]
Withheld
不适用
[Trial of device that is not approved or cleared by the U.S. FDA]NCT06733259[Redacted]
已完成
不适用
Clinical Investigation (Beta) of a New Developed Prosthetic KneeNCT06748729Össur Iceland ehf11
Withheld
不适用
[Trial of device that is not approved or cleared by the U.S. FDA]NCT06422065[Redacted]